Actuate Therapeutics SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

4Oct. 30, 2026, 5:05 p.m. ETView on SEC.gov
SCHEDULE 13GOct. 30, 2026, 4:05 p.m. ETView on SEC.gov
4Oct. 30, 2026, 3:37 p.m. ETView on SEC.gov
8-KOct. 30, 2026, 4:05 p.m. ETView on SEC.gov Our explainer
Delisting notice / failure to meet listing standard
AI summary, unreviewedActuate Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice, Adding to Existing MVLS Non-Compliance
4Oct. 29, 2026, 9:35 a.m. ETView on SEC.gov
8-KOct. 28, 2026, 5:17 p.m. ETView on SEC.gov
Entry into a material definitive agreement · Other events · Financial statements and exhibits
AI summary, unreviewedActuate Therapeutics Prices $11.0 Million Public Offering at $0.71 per Share-and-Warrant Set, Closes for Net Proceeds of About $9.96 Million
424B5Oct. 28, 2026, 8 a.m. ETView on SEC.gov
S-1/AOct. 19, 2026View on SEC.gov
S-1/AOct. 14, 2026View on SEC.gov
S-1Oct. 6, 2026View on SEC.gov
4Aug. 14, 2026, 5 p.m. ETView on SEC.gov
10-QAug. 14, 2026, 4:05 p.m. ETView on SEC.gov